- 1.
Kreftregisteret. Melanom i hud. https://www.kreftregisteret.no/Temasider/kreftformer/melanom/ Lest 9.5.2021.
- 2.
Helsedirektoratet. Maligne melanomer – handlingsprogram. Nasjonal faglig retningslinje. https://www.helsedirektoratet.no/retningslinjer/maligne-melanomer-handlingsprogram Lest 9.5.2021.
- 3.
Nasjonalt kvalitetsregister for melanom. Årsrapport 2020. https://www.kvalitetsregistre.no/sites/default/files/2021-10/%C3%85rsrapport%20Nasjonalt%20kvalitetsregister%20for%20melanom%202020.pdf Lest 7.9.2022.
- 4.
Robsahm TE, Helsing P, Nilssen Y et al. High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. Clin Epidemiol 2018; 10: 537–48. [PubMed][CrossRef]
- 5.
Haenssle HA, Korpas B, Hansen-Hagge C et al. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol 2010; 146: 257–64. [PubMed][CrossRef]
- 6.
Boniol M, Autier P, Boyle P et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345: e4757. [PubMed][CrossRef]
- 7.
Aitken JF, Youlden DR, Baade PD et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer 2018; 142: 1528–35. [PubMed][CrossRef]
- 8.
Pampena R, Kyrgidis A, Lallas A et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938–945.e4. [PubMed][CrossRef]
- 9.
Gachon J, Beaulieu P, Sei JF et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005; 141: 434–8. [PubMed][CrossRef]
- 10.
DermNet. Melanoma of the nail unit. https://dermnetnz.org/topics/melanoma-of-the-nail-unit Lest 12.5.2022.
- 11.
Swetter SM, Thompson JA, Albertini MR et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021; 19: 364–76. [PubMed][CrossRef]
- 12.
Verdens helseorganisasjon. WHO Classification of skin tumours. Lyon: WHO,2018: 66-75. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Skin-Tumours-2018 Lest 7.9.2022.
- 13.
Busam G. Scolyer. Pathology of melanocytic tumors. Elsevier 2019: 398-9.
- 14.
Curti BD, Faries MB. Recent Advances in the Treatment of Melanoma. N Engl J Med 2021; 384: 2229–40. [PubMed][CrossRef]
- 15.
Yao K, Balch G, Winchester DJ. Multidisciplinary treatment of primary melanoma. Surg Clin North Am 2009; 89: 267–81, xi. [PubMed][CrossRef]
- 16.
Leiter U, Stadler R, Mauch C et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol 2019; 37: 3000–8. [PubMed][CrossRef]
- 17.
Broman KK, Hughes TM, Dossett LA et al. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. J Am Coll Surg 2021; 232: 424–31. [PubMed][CrossRef]
- 18.
Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(6):472-92.
- 19.
Luke JJ, Ascierto PA, Carlino MS et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol 2020; 16: 4429–38. [PubMed][CrossRef]
- 20.
U.S. Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma Lest 31.8.2022.
- 21.
Weber J, Mandala M, Del Vecchio M et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377: 1824–35. [PubMed][CrossRef]
- 22.
Eggermont AMM, Blank CU, Mandala M et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378: 1789–801. [PubMed][CrossRef]
- 23.
Long GV, Hauschild A, Santinami M et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377: 1813–23. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.